Rituximab, mycophenolate mofetil compared for pemphigus vulgaris

(HealthDay)—For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in the New England Journal ...

Oncology & Cancer

Anti-cancer drug's mode of operation deciphered

Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. ...


Long-term rituximab may aid in antibody-associated vasculitis

For patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis ...

page 2 from 6